Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience
Nicola Maciocia(University College London), Neil Rabin(University College London), Faye Sharpley(Oxford University Hospitals NHS Trust), Ali Rismani(Whittington Hospital), Andrew Melville(University of Glasgow), Simon Cheesman(Royal London Hospital), Matthew Streetly(King's College - North Carolina), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Reuben Benjamin(King's College Hospital), Shirley D’Sa(University College Hospital), Stephen Schey(University College Hospital), Paul Maciocia(University College London Hospitals NHS Foundation Trust)
Cited by 2
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502